Education
About Us
Working with TipRanks
Follow Us
Turnstone Biologics Corp. (TSBX)
NASDAQ:TSBX
RESEARCH TOOLSreports
TSBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $3.88
Previous CloseN/A
Volume78.23K
Average Volume (3M)122.87K
Market Cap
$9.51M
Enterprise Value-$30.87M
Total Cash (Recent Filing)$34.73M
Total Debt (Recent Filing)$5.17M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
May 19, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding23,128,454
10 Day Avg. Volume88,531
30 Day Avg. Volume122,874
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)70.22
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-3.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.87
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$0.70Price Target Upside70.73% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Turnstone Biologics Corp. News
PremiumCompany Announcements
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company guides to a cash runway into the second quarter of 2026, providing a degree of financial stability.
Pre-clinical DevelopmentsThe company’s pre-clinical, next-generation TIL program, TIDAL-02, could deliver value to whomever picks up Turnstone’s mantle.
Research AdvancementsThe evidence that selecting a specific 12-genome signature meaningfully increases TIL yield and potency is encouraging for Turnstone Biologics.
Bears Say
Clinical Program DiscontinuationTurnstone Biologics announced the discontinuation of their lead (and sole) clinical program, TIDAL-01.
Financial EvaluationWith the removal of TIDAL-01 from estimates, the price target has been reduced to $1 from $3 and the MP rating is reiterated.
Workforce And OperationsA workforce reduction by 60% was recently implemented, indicating potential challenges within the company.
---
Ownership Overview
32.32%
Insiders
3.10% Mutual Funds
25.98% Other Institutional Investors
35.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TSBX FAQ
What was Turnstone Biologics Corp.’s price range in the past 12 months?
Turnstone Biologics Corp. lowest stock price was $0.34 and its highest was $3.88 in the past 12 months.
What is Turnstone Biologics Corp.’s market cap?
Turnstone Biologics Corp.’s market cap is $9.51M.
When is Turnstone Biologics Corp.’s upcoming earnings report date?
Turnstone Biologics Corp.’s upcoming earnings report date is May 19, 2025 which is in 49 days.
How were Turnstone Biologics Corp.’s earnings last quarter?
Turnstone Biologics Corp. released its earnings results on Mar 20, 2025. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.69 by $0.13.
Is Turnstone Biologics Corp. overvalued?
According to Wall Street analysts Turnstone Biologics Corp.’s price is currently Undervalued.
Does Turnstone Biologics Corp. pay dividends?
Turnstone Biologics Corp. does not currently pay dividends.
What is Turnstone Biologics Corp.’s EPS estimate?
Turnstone Biologics Corp.’s EPS estimate is -0.2.
How many shares outstanding does Turnstone Biologics Corp. have?
Turnstone Biologics Corp. has 23,128,454 shares outstanding.
What happened to Turnstone Biologics Corp.’s price movement after its last earnings report?
Turnstone Biologics Corp. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.69. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Turnstone Biologics Corp.?
Currently, no hedge funds are holding shares in TSBX
---
Company Description
Turnstone Biologics Corp.
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
---
TSBX Stock 12 Month Forecast
Average Price Target
$0.70
▲(70.73% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Kura Oncology
―
Allogene Therapeutics
―
Precision BioSciences
―
Best Analysts Covering TSBX
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-75.10%
reiterated a buy rating 7 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.10% per trade.
---